New immune therapy tested to boost stem cell transplant success for tough lymphomas
Disease control
Not yet recruiting
This study is testing a new immune-based drug called glofitamab for adults with an aggressive type of lymphoma (DLBCL) that has returned or not responded to initial chemotherapy. The goal is to see if using glofitamab before and/or after a stem cell transplant can help control th…
Phase: PHASE2 • Sponsor: American University of Beirut Medical Center • Aim: Disease control
Last updated Mar 09, 2026 14:26 UTC